Metastatic renal cancer is commonly treated with drugs that block tumor blood vessel growth, such as pazopanib. Response often cannot be determined accurately using standard imaging scans. In this study, we evaluated patients with a magnetic resonance imaging parameter that reflects tumor blood vessel changes. It declined consistently after treatment, and higher baseline values correlated with longer time to disease progression. Introduction/Background: Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is preceded by a rise in K trans level, a parameter derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) that reflects vascular permeability. We thus hypothesized that K trans might be a predictive biomarker for pazopanib. 
Introduction
Clear-cell renal cancer is characterized by inactivation of the von HippeleLindau pathway, which leads to upregulation of the hypoxia inducible factor 2a transcription factor and vascular endothelial growth factor (VEGF). 1 This process results in angio-outcome because these drugs often result in growth inhibition, as opposed to direct cytotoxicity. 4 Thus, it remains difficult to determine whether a patient continues to derive benefit from treatment at clinical reassessment with each cycle. Because these agents can have significant toxicities that affect quality of life, identification and validation of novel biomarkers in this space is critical. Quantitative and semiquantitative parameters derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) have been identified as biomarkers for VEGF pathwaydirected agents. [4] [5] [6] [7] [8] Some studies have also shown predictive and prognostic value for DCE-MRI-based biomarkers. 6, 7 K trans is one parameter that reflects perfusion rate and capillary permeability. Studies in renal cancer have shown that it declines an average of 30% upon treatment with VEGF-targeted therapy, making it a potentially important pharmacodynamic biomarker. 6, 7, 9 The initial change in K trans is dose-dependent, but has not been shown to correlate with time to progression in previous studies. There remains limited clinical data on longitudinal assessment of K trans during VEGF pathway-directed therapy. Preclinical animal models strongly suggest that changes in blood flow and perfusion, assessed according to K trans , precede tumor growth. 10, 11 We thus hypothesized that recovery of K trans is predictive of progression in metastatic renal cancer patients treated with pazopanib. To address this question, we conducted a clinical trial with serial assessments of K trans during treatment with pazopanib for patients with metastatic renal cancer.
Patients and Methods

Patients
Patients with histologically confirmed metastatic clear-cell renal cancer without previous pazopanib therapy were eligible. Other requirements included measurable disease with at least 1 lesion in the abdomen or pelvis !20 mm on MRI or computed tomography (CT) scan, World Health Organization performance status 0 to 2, and normal organ function defined as glomerular filtration rate (GFR) > 30 mL/min, aspartate aminotransferase/alanine aminotransferase 2.5 times the upper limit of normal, and total bilirubin 1.5 the upper limit of normal. Exclusion criteria included patients with central nervous system metastases, uncontrolled hypertension (defined as systolic blood pressure !140 mm Hg or diastolic blood pressure !90 mm Hg), pregnancy, and anticancer therapy within 14 days of study enrollment.
Study Design
Patients were treated with pazopanib 800 mg oral daily without food in 28-day cycles until disease progression measured using Response Evaluation Criteria in Solid Tumors. Standard MRI of the abdomen and pelvis was obtained at baseline and every 8 weeks AE 1 week for tumor burden assessment. An investigational DCE sequence was added to the standard image acquisition sequences to calculate K trans and associated physiologic parameters. An additional investigational DCE-MRI imaging procedure was conducted 1 week AE 1 day after initiation of drug therapy. The protocol included a total of 5 DCE-MRI procedures per patient. Toxicity monitoring using National Cancer Institute Common Toxicity Criteria version 3.0 was performed and dose modifications made for Grade 3 or 4 toxicities. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the University of Chicago's institutional review board.
Magnetic Resonance Imaging Acquisition
Magnetic resonance images were acquired using a 1.5T Philips Achieva scanner (Philips Healthcare, Andover, MA), using an 8-channel torso local coil. Gadobenate dimeglumine (Multihance; Bracco, Cranbury Township, NJ) was used as the contrast agent, at a standard dose of 0.1 mmol/kg (0.2 mL/kg Research sequences were acquired in a 36-mm thick axial slab centered over the largest cross-section of a selected metastatic lesion in an area with minimal MRI, especially motion-related, artifacts. Limited coverage was necessary to insure high temporal resolution with adequate signal to noise ratios. The location of the slab was determined by the clinical radiologist (A.O.) on the basis of previous CT or MRI, and was selected at the level of largest lesion cross-section. The location of the slab was kept constant in subsequent scans, relative to the spine. An axial nonfat suppressed T1-weighted dual-echo DCE-MRI 3-D sequence (TR/TE1/TE2 ¼ 8.5/3.0/6.0 ms, flip angle ¼ 10 , in-plane resolution ¼ 2 mm, field of view ¼ 380 Â 356 mm, slice thickness ¼ 3 mm acquired and reconstructed, number of slices ¼ 12, partial Fourier factors ¼ 0.7 and 0.85 in the Y and Z directions, sensitivity encoding acceleration factor ¼ 1.2 in the anterior/posterior direction, time resolution ¼ 9.8 s) was acquired for 16 minutes, with 10 dynamic phases acquired before contrast agent injection, and the rest acquired after contrast injection. The clinical delayed-phase whole abdomen T1-weighted sequence was nested into the research DCE-MRI sequence at 3 minutes after contrast administration, which did not affect the gain or other prescan parameters.
Contrast Agent Concentration Calculation
Contrast agent concentration was calculated as an average over regions of interest (ROIs) outlined over the lesion, muscle, and adipose tissue, and over the aorta cross-section in slices in which they were visible. The edge slices (first and last 3 slices) had reduced flip angles because of the nonideal slab profile, and were not used for calculation. Concentration versus time curves for lesion, muscle, and arterial ROIs were calculated using the reference tissue method published earlier. 12 In short, the approximate inverse proportionality of signal to T1 in the short TR T1-weighted DCE-MRI sequence was used. On the basis of the tabulated value of native T1 in adipose tissue (T1 ref ¼ 288 ms), 13 208 -Clinical Genitourinary Cancer April 2017
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and its average precontrast signal intensity S ref (0), the precontrast and postcontrast T1, and hence the contrast agent concentration as a function of time C(t) in each ROI could be approximated using Equation 1:
where R ¼ 5.6 L/mmol/s (obtained from the manufacturer data sheet) is the relaxivity of the contrast agent at 1.5T, and S(0) and S(t) are average signal in the ROI before contrast administration and as a function of time, respectively.
K trans Calculation
Before further analysis, the C(t) curves for tumor and muscle were smoothed via a fit to the 5-parameter empirical mathematical model, shown previously to provide excellent fits to the concentration uptake curves in tissues.
14-16 Two-compartment modeling 17 was used to iteratively fit smoothed C(t) curves to Equation 2:
where K trans is the volume transfer constant between the intravascular extracellular space and extravascular extracellular space (EES), v e is the volume of EES per unit volume of tissue, and C p (t) is the arterial input function (AIF). The AIF was obtained as the contrast concentration curve from the arterial ROI for each patient, and was corrected for hematocrit by dividing the contrast agent concentration in the arterial ROI by (1 hematocrit), with hematocrit ¼ 0.45; C p (t) ¼ C arterial (t)/ (1À0.45).
Statistical Analysis
The primary study end point was to determine whether a rise in K trans from nadir is predictive of subsequent tumor growth. Secondary end points included the association between changes in K trans and pazopanib therapy. The predefined principal metric assessed, R, was the log ratio of K trans at time t i to the lowest K trans among the first 2 (baseline or 1 week after therapy), a timedependent covariate. The main analysis was to assess whether the time-dependent variable R had a significant effect on the hazard rate for disease progression in a Cox proportional hazards model also incorporating a baseline clinical prognostic index (good/intermediate/poor) 18, 19 and previous VEGF pathway inhibitor therapy (yes/ no) as covariates. We assumed that the median time to progression in this patient population is 8 months and that K trans variability and change with therapy are similar to that seen in previous studies. 9 Exploratory objectives included correlating baseline K trans with progression-free survival (PFS). KaplaneMeier estimates and log rank tests were computed to evaluate the association between changes in K trans and PFS.
Trial size was on the basis of previous data showing that the standard deviation in R from baseline to 4 weeks was approximately 0.40. 9 A clinically meaningful effect was defined as a 50% increase in the hazard rate per 1 SD increase in R. To have 80% power to detect an effect of this magnitude, a total of 48 events (disease progressions) were required. Assuming a median time to progression of 8 months, enrollment of 65 patients was planned.
Results
Patient Characteristics and Feasibility of a Complex Biomarker Assessment
Because of poor accrual the study was closed after 20 patients were enrolled over the course of 2 years. Baseline characteristics of patients are summarized in 
Not reported 3
Number of Previous Therapies 
K trans and Clinical Outcome
The median PFS was 32.1 weeks. KaplaneMeier analysis showed a significant difference in PFS in patients grouped dichotomously around the median baseline K trans (P ¼ .036, log rank; Figure 2A ).
Patients with higher baseline values showed deeper reductions in K trans after therapy ( Figure 2B and C). The mean percent reduction in K trans after 1 week of therapy was 61.8% in the group with higher baseline values versus 9.2% in the group with lower baseline values (P ¼ .017, 2-tailed t test). Baseline K trans did not reach significance in a Cox proportional hazard model including clinical prognostic index and previous treatments (P ¼ .083). With our accrued sample size, the primary study end point, whether K trans recovery as a timedependent covariate affected hazard rate for disease progression, could not be assessed. with PFS, an observation that is consistent with data reported in previous studies. 9 We also found that higher baseline K trans was associated with deeper declines at week 1. Although there might be difficulty in using absolute baseline K trans levels between different populations, the percent reduction from baseline could be assessed at week 1 for an individual patient and might be consistent and reliable predictive measure to evaluate in future studies.
Conclusion
Despite not reaching its primary end point, this study was unique as the first to report serial DCE-MRI evaluations longitudinally over 24 weeks in renal cancer patients treated with VEGF therapy. It also showed the feasibility of performing a complex biomarker study using a multidisciplinary team of investigators. There remain challenges in the recruitment of patients for a study evaluating a novel biomarker for an FDA-approved therapy. Nonetheless, this study validated DCEeMRI-derived K trans as a noninvasive, pharmacodynamic biomarker. Its baseline value correlates with PFS for pazopanib therapy in metastatic renal cancer, thus showing its consistency across different antiangiogenic drug therapies.
Clinical Practice Points
Dynamic contrast-enhanced MRI is an emerging modality with potentially more sensitivity in assessing tumor growth compared with traditional imaging. K trans is an important DCEeMRI-derived parameter that changes with alteration in tumor vascular permeability.
Clinical studies have shown that in some cancers, such as renal carcinoma, K trans declines shortly after initiation of VEGFtargeted therapies. This study is the first to describe longitudinal serial assessments of K trans in metastatic renal cancer patients treated with pazopanib. We report that K trans consistently declined upon initiation of therapy, and that higher baseline K trans correlated with longer PFS.
The data reported have implications for future studies using DCE-MRI as a pharmacodynamic biomarker. This technique might ultimately lead to more accurate tools to determine disease progression at an earlier time point than traditional imaging assessment, which could inform therapeutic changes at an earlier time point when treatment is no longer effective and possibly still causing toxicities and affecting quality of life.
